Esthesioneuroblastoma: Mansoura University Hospitals’ experience with multimodality therapy in 10 years

BackgroundEsthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare and aggressive malignant tumour of the nasal cavity and paranasal sinuses. This study was conducted to evaluate and analyse the outcomes of the combined modality regimen including surgery, radiotherapy and chemotherapy.MethodsFrom January 2001 to January 2012; in a retrospective analysis; 10 patients with ENB were treated in Mansoura University Hospitals at the Otolaryngology Department. Four patients were of Kadish stage B and six were of stage C. In four cases of stage C, invasion of the anterior cranial fossa was detected. No patient had lymph nodes or distant metastases. All patients received a combined multimodality treatment including surgery; craniofacial or endoscopic resections; radiotherapy and combined vepesid and cisplatin chemotherapy.ResultsNine patients, over an average follow-up which ranged from 5 to 8 years (mean 6.2; SD 3.01), are actually alive with no evidence of disease in eight patients and locoregional recurrence in one patient who underwent salvage therapy. However, the overall survival of the nine patients was 5.3–8.75 years (mean 6.4; SD 3.04). Local recurrence and distant metastasis were detected in one patient with an average survival of 3 years.ConclusionsENB can be a highly curable sinonasal malignancy. Combined modality treatment is considered an integral part of management protocol.